Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
kidney cancer
Pharma
FDA signs off on Merck’s Welireg to treat adrenal system tumors
The FDA approved a third indication for Merck's Welireg, signing off on it as a treatment for a rare condition that causes adrenal system tumors.
Kevin Dunleavy
May 15, 2025 10:43am
Exelixis shifts focus as triplet misses OS mark in kidney cancer
Feb 18, 2025 1:30pm
Merck's Welireg again comes up short in OS but excels in PFS
Sep 13, 2024 8:00am
BMS' Opdivo, Aveo's Fotivda fail as combo in kidney cancer
Jul 18, 2024 4:26pm
ASCO: Merck KGaA's Bavencio combo misses survival mark in RCC
May 23, 2024 5:00pm
BMS touts latest Opdivo data as I-O battle heads to new front
Jan 29, 2024 8:45am
